Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells $87,684.02 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total value of $87,684.02. Following the completion of the transaction, the director now directly owns 7,229,861 shares in the company, valued at approximately $55,380,735.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.82, for a total value of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.79, for a total value of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total value of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total value of $106,457.10.
• On Tuesday, January 23rd, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.58, for a total value of $212,171.32.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $7.35 on Friday. The stock’s 50-day simple moving average is $10.73 and its 200 day simple moving average is $9.09. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.54 and a 52-week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. The business had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. KeyCorp upped their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Finally, TD Cowen started coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They set a “market perform” rating on the stock. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.75.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in RXRX. Swiss National Bank increased its stake in Recursion Pharmaceuticals by 7.6% in the 1st quarter. Swiss National Bank now owns 94,300 shares of the company’s stock worth $675,000 after acquiring an additional 6,700 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Recursion Pharmaceuticals by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company’s stock worth $2,676,000 after acquiring an additional 6,294 shares during the last quarter. MetLife Investment Management LLC increased its stake in Recursion Pharmaceuticals by 55.4% in the 1st quarter. MetLife Investment Management LLC now owns 64,035 shares of the company’s stock worth $458,000 after acquiring an additional 22,833 shares during the last quarter. Rhumbline Advisers increased its stake in Recursion Pharmaceuticals by 4.0% in the 1st quarter. Rhumbline Advisers now owns 123,892 shares of the company’s stock worth $887,000 after acquiring an additional 4,818 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Recursion Pharmaceuticals by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company’s stock worth $47,338,000 after acquiring an additional 497,504 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.